Clinical Trial Update: Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years [Phase 1]

View source ↗

Summary

Phase I first-in-human study evaluating safety and tolerability of EuRSV in healthy adults aged 19–80. The trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• EuRSV

Snippet

Sponsor: EuBiologics Co.,Ltd | Conditions: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV) | Phase 1 | Status: ACTIVE_NOT_RECRUITING